Imidapril

Imidapril

SCHEMBL22492310

CCOC(=O)C(CCc1ccccc1)NC(C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Imidapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ ACE known ✓ P12821 13/20 1.00
▸ LMNA P02545 2/20 0.66
▸ ABCB11 O95342 2/20 0.64
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ USP2 O75604 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imidapril SCHEMBL12894585 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL34098 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL3193644 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL11014327 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL34099 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL683273 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL7354516 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL6516062 1.00 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL7294155 0.99 ACE (0.98) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL136722 0.99 ACE (0.98) ACELMNAABCB11MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744654-A1 SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY Anavex Life Sciences Corp. (US) 2026-05-20 — — EP disclosed
US-12280034-B2 Sigma-1 receptor agonist systolic blood pressure therapy ANAVEX LIFE SCIENCES CORP. (US) 2025-04-22 — — US disclosed
CN-118067870-A Rapid screening method for nebivolol and imidapril 苏州市药品检验检测研究中心(苏州市药品不良反应监测中心) 2024-05-24 — — CN disclosed
US-11622955-B2 Sigma-1 receptor agonist systolic blood pressure therapy ANAVEX LIFE SCIENCES CORP. (US) 2023-04-11 — — US disclosed
US-20230071766-A1 SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY ANAVEX LIFE SCIENCES CORP. (US) 2023-03-09 — — US disclosed
US-20210186920-A1 SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY ANAVEX LIFE SCIENCES CORP. (US) 2021-06-24 — — US disclosed
US-20210145964-A1 STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS ACADEMISCH MEDISCH CENTRUM (NL) 2021-05-20 — — US disclosed
CN-105713068-B Method for preparing imidapril key intermediate and derivative thereof 湖南九典制药股份有限公司 2021-04-20 — — CN disclosed
EP-3716968-A1 SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY Anavex Life Sciences Corp. (US) 2020-10-07 — — EP disclosed
CN-111712241-A Sigma-1 receptor agonist systolic blood pressure therapy 阿纳韦克斯生命科学公司 2020-09-25 — — CN disclosed
CN-104119424-B The preparation method of (4S) -3- [(2S) -2 [(1S) -1- ethoxycarbonyl-3-phenylpropyl] aminopropionyl] -1- methyl -2- oxoimidazolinium -4- carboxylic acid 上海天慈生物谷生物工程有限公司 2018-12-18 — — CN disclosed
CN-104119424-B The preparation method of (4S) -3- [(2S) -2 [(1S) -1- ethoxycarbonyl-3-phenylpropyl] aminopropionyl] -1- methyl -2- oxoimidazolinium -4- carboxylic acid 上海天慈生物谷生物工程有限公司 2018-12-18 — — CN disclosed
Send feedback